These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 27495988)

  • 1. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.
    Ahn DH; Javle M; Ahn CW; Jain A; Mikhail S; Noonan AM; Ciombor K; Wu C; Shroff RT; Chen JL; Bekaii-Saab T
    Cancer; 2016 Dec; 122(23):3657-3666. PubMed ID: 27495988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
    Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.
    Feng F; Cheng Q; Zhang D; Li B; Qin H; Xu C; Han M; Yu Y; Li Z; Li JY; Qiu Z; Xiong L; Liu C; Li F; Yi B; Jiang X
    Oncol Rep; 2020 Apr; 43(4):1089-1102. PubMed ID: 32323774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.
    Brieau B; Dahan L; De Rycke Y; Boussaha T; Vasseur P; Tougeron D; Lecomte T; Coriat R; Bachet JB; Claudez P; Zaanan A; Soibinet P; Desrame J; Thirot-Bidault A; Trouilloud I; Mary F; Marthey L; Taieb J; Cacheux W; Lièvre A
    Cancer; 2015 Sep; 121(18):3290-7. PubMed ID: 26052689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers.
    Høgdall D; O'Rourke CJ; Dehlendorff C; Larsen OF; Jensen LH; Johansen AZ; Dang H; Factor VM; Grunnet M; Mau-Sørensen M; Oliveira DVNP; Linnemann D; Boisen MK; Wang XW; Johansen JS; Andersen JB
    Clin Cancer Res; 2020 Nov; 26(21):5655-5667. PubMed ID: 32933994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis.
    Hwang IG; Song HS; Lee MA; Nam EM; Lim J; Lee KH; Lee KT; Zang DY; Jang JS
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1291-6. PubMed ID: 25326056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
    Novarino AM; Satolli MA; Chiappino I; Giacobino A; Napoletano R; Ceccarelli M; Ciccone G; Schena M; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2013 Oct; 36(5):466-71. PubMed ID: 22781390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
    Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
    Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
    Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
    Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
    Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.
    Park K; Kim KP; Park S; Chang HM
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):13-20. PubMed ID: 27770489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.
    Peraldo-Neia C; Cavalloni G; Fenocchio E; Cagnazzo C; Gammaitoni L; Cereda S; Nasti G; Satolli MA; Aprile G; Reni M; Avallone A; Spadi R; Venesio T; Martin V; Doglioni C; Frattini M; Aglietta M; Leone F
    PLoS One; 2018; 13(1):e0191593. PubMed ID: 29352306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
    Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
    World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
    Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis.
    Yang R; Wang B; Chen YJ; Li HB; Hu JB; Zou SQ
    Anticancer Drugs; 2013 Sep; 24(8):871-7. PubMed ID: 23799294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience.
    Wu CE; Chou WC; Hsieh CH; Chang JW; Lin CY; Yeh CN; Chen JS
    BMC Cancer; 2020 May; 20(1):422. PubMed ID: 32410631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.
    Fornaro L; Vivaldi C; Cereda S; Leone F; Aprile G; Lonardi S; Silvestris N; Santini D; Milella M; Caparello C; Musettini G; Pasquini G; Falcone A; Brandi G; Sperduti I; Vasile E;
    J Exp Clin Cancer Res; 2015 Dec; 34():156. PubMed ID: 26693938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.